Secunderabad Chronicle

Type 1 Diabetes Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects

 Breaking News
  • No posts were found

Type 1 Diabetes Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects

May 11
19:44 2023
Type 1 Diabetes Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 1 Diabetes pipeline constitutes 100+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Type 1 Diabetes Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Type 1 Diabetes Market.

 

The Type 1 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Type 1 Diabetes Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Type 1 Diabetes treatment therapies with a considerable amount of success over the years. 
  • Type 1 Diabetes companies working in the treatment market are Arecor, Novo Nordisk, Novartis, ILTOO Pharma, ImCyse, Zealand Pharma, Eli Lilly and Company, Dompe Farmaceutici, Prevention Bio, Eledon Pharmaceutical, Avotres, ImCyse, Landos Biopharma, Panbela Therapeutics, Novo Nordisk, Vertex Pharmaceuticals, Histogen, and others, are developing therapies for the Type 1 Diabetes treatment 
  • Emerging Type 1 Diabetes therapies such as – AT247, NNC0471-0119, MHS552, ILT-101, IMCY-0098, Iscalimab, Dasiglucagon, LY3209590, Ladarixin, Teplizumab, AT-1501, AVT001, IMCY-0098, LABP 111, Eflornithine, NNC0363 0845, VX-880, Emricasan, and others are expected to have a significant impact on the Type 1 Diabetes market in the coming years.   
  • In April 2022, The National Institute of Diabetes and Digestive Kidney Disease (NIDDK) awarded AVM Biotechnology a $1.6 million Small Business Innovation Research (SBIR) grant to research its small molecule, AVM0703, for treating Type 1 diabetes (T1D). The most recent award will enable the business to conduct more research into the use of AVM0703 as a single agent and as part of a combination therapy for reversing recently developed and chronic T1D
  • In June 2022, The Phase I/II clinical trial of VX-880, an investigational fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) who have impaired hypoglycemia awareness and severe hypoglycemia, has been released from the clinical hold, according to Vertex Pharmaceuticals
  • In May 2022, with great pleasure, Sernova and Evotec announce their exclusive global strategic alliance to create the greatest cell therapy treatment available for persons with insulin-dependent diabetes. Through the partnership, Sernova will have the sole global right to licence Evotec’s iPSC-derived beta cells for the treatment of both type 1 and type 2 diabetes. Evotec has made a strategic equity investment of €15M and will make an additional investment of €5M in addition to signing the collaboration agreement
  • In July 2022, Vertex Pharmaceuticals revealed that it has signed a legally binding agreement to buy privately held biotechnology company ViaCyte for $320 million in cash. ViaCyte specialises in providing novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D)

 

Type 1 Diabetes Overview

An autoimmune disease known as type 1 diabetes causes the pancreatic insulin-producing cells to be attacked by the immune system. What triggers this autoimmune response is unknown. There is no relationship between type 1 diabetes and alterable lifestyle factors.

 

Get a Free Sample PDF Report to know more about Type 1 Diabetes Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight

 

Emerging Type 1 Diabetes Drugs Under Different Phases of Clinical Development Include:

  • AT247: Arecor
  • NNC0471-0119: Novo Nordisk
  • MHS552: Novartis
  • ILT-101: ILTOO Pharma
  • IMCY-0098: ImCyse
  • Iscalimab: Novartis
  • Dasiglucagon: Zealand Pharma
  • LY3209590: Eli Lilly and Company
  • Ladarixin: Dompe Farmaceutici
  • Teplizumab: Prevention Bio
  • AT-1501: Eledon Pharmaceutical
  • AVT001: Avotres
  • IMCY-0098: ImCyse
  • LABP 111: Landos Biopharma
  • Eflornithine: Panbela Therapeutics
  • NNC0363 0845: Novo Nordisk
  • VX-880: Vertex Pharmaceuticals
  • Emricasan: Histogen
  • Iscalimab: Novartis

 

Route of Administration

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Type 1 Diabetes Pipeline Therapeutics Assessment

  • Type 1 Diabetes Assessment by Product Type
  • Type 1 Diabetes By Stage and Product Type
  • Type 1 Diabetes Assessment by Route of Administration
  • Type 1 Diabetes By Stage and Route of Administration
  • Type 1 Diabetes Assessment by Molecule Type
  • Type 1 Diabetes by Stage and Molecule Type

 

DelveInsight’s Type 1 Diabetes Report covers around 5+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Type 1 Diabetes product details are provided in the report. Download the Type 1 Diabetes pipeline report to learn more about the emerging Type 1 Diabetes therapies

 

Some of the key companies in the Type 1 Diabetes Therapeutics Market include:

Key companies developing therapies for Type 1 Diabetes are – Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Landos Biopharma, Zealand Pharma,  Prevention Bio, Histogen, Vertex Pharmaceuticals, Eledon Pharmaceuticals, Avotres , Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy,  SQZ Biotech, Enthera, and others.

 

Type 1 Diabetes Pipeline Analysis:

The Type 1 Diabetes pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.
  • Type 1 Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Type 1 Diabetes drugs and therapies

 

Type 1 Diabetes Pipeline Market Drivers

  • Rising prevalence of type-1 diabetes due to environmental and genetic factors, growing geriatric population, which is susceptible to type-1 diabetes, increasing prevalence of obesity, which is a contributing factor are some of the important factors that are fueling the Type 1 Diabetes Market.

 

Type 1 Diabetes Pipeline Market Barriers

  • However, lack of awareness among patients regarding types of treatment available, strict approval process and side effects associated with the treatment may restrict market growth and other factors are creating obstacles in the Type 1 Diabetes Market growth.

 

Scope of Type 1 Diabetes Pipeline Drug Insight    

  • Coverage: Global
  • Key Type 1 Diabetes Companies: Arecor, Novo Nordisk, Novartis, ILTOO Pharma, ImCyse, Zealand Pharma, Eli Lilly and Company, Dompe Farmaceutici, Prevention Bio, Eledon Pharmaceutical, Avotres, ImCyse, Landos Biopharma, Panbela Therapeutics, Novo Nordisk, Vertex Pharmaceuticals, Histogen, and others
  • Key Type 1 Diabetes Therapies: AT247, NNC0471-0119, MHS552, ILT-101, IMCY-0098, Iscalimab, Dasiglucagon, LY3209590, Ladarixin, Teplizumab, AT-1501, AVT001, IMCY-0098, LABP 111, Eflornithine, NNC0363 0845, VX-880, Emricasan, and others
  • Type 1 Diabetes Therapeutic Assessment: Type 1 Diabetes current marketed and Type 1 Diabetes emerging therapies
  • Type 1 Diabetes Market Dynamics: Type 1 Diabetes market drivers and Type 1 Diabetes market barriers 

 

Request for Sample PDF Report for Type 1 Diabetes Pipeline Assessment and clinical trials

 

Table of Contents

1

Type 1 Diabetes Report Introduction

2

Type 1 Diabetes Executive Summary

3

Type 1 Diabetes Overview

4

Type 1 Diabetes- Analytical Perspective In-depth Commercial Assessment

5

Type 1 Diabetes Pipeline Therapeutics

6

Type 1 Diabetes Late Stage Products (Phase II/III)

7

Type 1 Diabetes Mid Stage Products (Phase II)

8

Type 1 Diabetes Early Stage Products (Phase I)

9

Type 1 Diabetes Preclinical Stage Products

10

Type 1 Diabetes Therapeutics Assessment

11

Type 1 Diabetes Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Type 1 Diabetes Key Companies

14

Type 1 Diabetes Key Products

15

Type 1 Diabetes Unmet Needs

16 

Type 1 Diabetes Market Drivers and Barriers

17

Type 1 Diabetes Future Perspectives and Conclusion

18

Type 1 Diabetes Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles